Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Del Papa

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Leukemia|January 26, 2007
Chronic myeloproliferative disorders: the bone marrow stromal component is not involved in the malignant cloneM Di Ianni, L Moretti, B Del Papa, et al.
Leukemia|August 11, 2006
A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disordersM Di Ianni, L Moretti, B Del Papa, et al.
Blood Cells, Molecules & Diseases|November 6, 2004
Mesenchymal cells: a vehicle for gene therapyM Di Ianni, B Del Papa, M De Ioanni, et al.
Clinical and Experimental Immunology|April 24, 2013
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapyP Cipriani, P Di Benedetto, V Liakouli, et al.
Leukemia|November 27, 2014
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutationF De Falco, R Sabatini, F Falzetti, et al.
Leukemia|November 2, 2013
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemiaP Sportoletti, S Baldoni, B Del Papa, et al.
Clinical and Experimental Immunology|March 19, 2009
Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applicationsM Di Ianni, B Del Papa, D Cecchini, et al.
Leukemia|April 30, 2016
The NOTCH1/CD39 axis: a Treg trip-switch for GvHDB Del Papa, A Pierini, P Sportoletti, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Leukemia|January 26, 2007
Chronic myeloproliferative disorders: the bone marrow stromal component is not involved in the malignant cloneM Di Ianni, L Moretti, B Del Papa, et al.
Leukemia|August 11, 2006
A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disordersM Di Ianni, L Moretti, B Del Papa, et al.
Blood Cells, Molecules & Diseases|November 6, 2004
Mesenchymal cells: a vehicle for gene therapyM Di Ianni, B Del Papa, M De Ioanni, et al.
Clinical and Experimental Immunology|April 24, 2013
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapyP Cipriani, P Di Benedetto, V Liakouli, et al.
Leukemia|November 27, 2014
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutationF De Falco, R Sabatini, F Falzetti, et al.
Leukemia|November 2, 2013
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemiaP Sportoletti, S Baldoni, B Del Papa, et al.
Clinical and Experimental Immunology|March 19, 2009
Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applicationsM Di Ianni, B Del Papa, D Cecchini, et al.
Leukemia|April 30, 2016
The NOTCH1/CD39 axis: a Treg trip-switch for GvHDB Del Papa, A Pierini, P Sportoletti, et al.
Pageof 1